Johannes Goebel

Learn More
Daclizumab, a humanized antibody against the interleukin-2 (IL-2) receptor (R) alpha-chain, is a promising new immunosuppressant in transplantation. As its exact mechanism of action has remained unclear, we examined its short-term effects on primary human T lymphocytes expressing the high-affinity IL-2R. Daclizumab exposure for 20 min neither affected T(More)
The lack of development environments for interdisciplinary research conducted on large-scale datasets hampers research at every stage. Projects incur large startup costs as disparate infrastructure is assembled; experimentation slows when software components and environment are mismatched for specific research tasks; and findings are disseminated in forms(More)
  • 1